A PHASE II STUDY OF THE COMBINATION OF GEMCITABINE AND IMATINIB MESYLATE IN PRETREATED PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA

Registry ID

EUCTR2014-002876-10

Source registry

EUCTR

Status

Ongoing

Phase

PHASE2

Sponsor

Istituto Clinico Humanitas

Start date

2014-10-31

Last update

2026-08-16

Conditions

• Malignant Pleural Mesothelioma

Summary

- To assess the anti-tumor activity of IM in combination with GEM, in terms of 3-months progression-free survival (PFS) rate.

Locations

• , , Italy

Related clinical trials

• APG-2449 in Patients With Advanced Solid Tumors
• Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
• Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma
• The IMmunotherapy Pleural 5-ALA PDT
• Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
• Hemithoracic Arc Radiotherapy Post Pleural Decortication

View on source registry